Wills Financial Group LLC Lowers Stock Holdings in Merck & Co., Inc. $MRK

Wills Financial Group LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK) by 48.0% during the fourth quarter, HoldingsChannel reports. The firm owned 16,955 shares of the company’s stock after selling 15,665 shares during the quarter. Wills Financial Group LLC’s holdings in Merck & Co., Inc. were worth $1,785,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the stock. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the 4th quarter valued at $25,000. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the 3rd quarter worth $31,000. High Note Wealth LLC lifted its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the period. Tucker Asset Management LLC acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $34,000. Finally, Wealth Watch Advisors INC purchased a new stake in shares of Merck & Co., Inc. in the third quarter valued at about $34,000. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $119.54 on Wednesday. The company has a market cap of $295.24 billion, a price-to-earnings ratio of 33.67, a price-to-earnings-growth ratio of 2.69 and a beta of 0.21. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock’s 50-day moving average is $116.56 and its 200-day moving average is $112.85.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Equities analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.8%. Merck & Co., Inc.’s payout ratio is 95.77%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MRK. Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. Citigroup began coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research note on Monday, April 6th. Finally, UBS Group raised their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Gilead reported positive Phase 3 results for their once-weekly HIV regimen islatravir/lenacapavir, meeting the primary efficacy endpoint in both studies and moving the program closer to regulatory filings. Article: Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
• Positive Sentiment: The HIV data could strengthen Merck’s long-term pipeline and add a potential new growth driver if the once-weekly treatment wins approval and commercialization proceeds as expected. Article: Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
• Neutral Sentiment: Merck also presented at the Goldman Sachs 47th Annual Global Healthcare Conference, which typically reinforces management’s strategy and pipeline commentary but does not by itself change fundamentals. Article: Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Merck’s collaboration with The Hashgraph Group on an EU digital product passport for regulated supply chains is strategically interesting, but it is unlikely to have a near-term material impact on earnings. Article: The Hashgraph Group and Merck Introduce EU Digital Product Passport on Hedera for Regulated Supply Chains
• Negative Sentiment: Merck and Gilead discontinued a Phase 3 non-small cell lung cancer study after it failed to show a statistically significant benefit, which removes one potential oncology catalyst and highlights clinical risk in the pipeline. Article: Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
• Negative Sentiment: Reuters also reported Merck is exploring treatment options for a rare Ebola strain, which may reflect additional research effort but could carry uncertainty around development timing and commercial value. Article: Merck (MRK) Explores Treatment Options for Rare Ebola Strain, Reuters Reports

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.